Why You Never Feel Full: Leptin Resistance and What It Means

When leptin was discovered in 1994 by Jeffrey Friedman's group at Rockefeller University, it looked like the answer to obesity. Here was a hormone secreted by fat tissue that travelled to the brain and told the hypothalamus, in essence, "you have enough energy stored — you can stop eating now." Mice that lacked the gene for leptin grew enormous; injecting them with the hormone caused them to lose weight rapidly. The path forward seemed obvious. Find people with obesity, give them leptin, and the problem would resolve.

That trial happened. In 1999, Steven Heymsfield led a multicentre study of recombinant human leptin in people with obesity. The results were a disappointment that has shaped the field ever since. At ordinary doses, leptin produced essentially no weight loss. At extremely high doses, some patients lost a few kilograms — but the magnitude was modest, the side effects significant, and the drug never made it to market for common obesity. Something was wrong with the model.

The explanation that emerged from the next decade of research is now central to how endocrinologists think about appetite regulation. People with obesity are not, with rare exceptions, leptin-deficient. They have plenty of leptin — in many cases, three to four times the amount of lean controls. The signal is being sent. The hypothalamus has stopped responding to it.

What leptin resistance actually is

The phrase "leptin resistance" is borrowed by analogy from insulin resistance. In both cases, the relevant hormone is circulating at adequate or elevated levels, but the target tissue has lost sensitivity to it. The hypothalamus — specifically the arcuate nucleus, where POMC and AgRP neurons integrate appetite signalling — no longer reduces hunger drive in response to the leptin in the bloodstream. The result is that the brain reads the body's energy status as inadequate even when fat stores are abundant. Hunger persists. Satiety arrives later, or not at all. Energy expenditure runs as if the body were underfed.

Martin Myers at the University of Michigan has produced some of the cleanest mechanistic work on how this resistance develops. His group has identified at least three distinct failure points: impaired leptin transport across the blood-brain barrier (less of the hormone reaches the hypothalamus to begin with), inflammation in hypothalamic tissue that disrupts intracellular signalling, and upregulation of SOCS3, an intracellular protein that brakes the leptin receptor's downstream signalling cascade. Chronic high-fat diets in animal models reproduce all three. So does sustained obesity in humans.

The clinical picture is consistent with what patients describe. People with leptin resistance often report that they do not feel full after meals that would satisfy a lean person. They wake up hungry. The hunger that arrives between meals is the same hunger that would arrive in someone whose body genuinely needed food. The signal saying "stop eating" has been turned down at the receiving end. The signal saying "eat" hasn't.

Why the leptin trial failed

The Heymsfield trial's near-null result was, in retrospect, the most useful piece of information that early leptin therapeutics produced. If the problem were leptin deficiency, exogenous leptin would have worked. It didn't. The hypothalamus's reduced responsiveness meant that adding more of the same signal simply hit the same resistance.

There is a narrow population for whom leptin therapy does work spectacularly: people with rare congenital leptin deficiency, who lack the hormone entirely. A handful of cases worldwide, mostly identified in childhood, have been treated successfully. Their hypothalamus retains normal leptin sensitivity because it has never been exposed to chronic high leptin levels. The contrast with the common-obesity population is exactly what the resistance hypothesis predicts.

Metreleptin, the approved recombinant leptin, is now used in lipodystrophy syndromes — conditions where fat tissue is absent and leptin is genuinely low. In ordinary obesity, where fat tissue is abundant and leptin is high, it does little. The therapy and the indication match the underlying biology.

Why dieting makes it worse

Weight loss reduces fat tissue, which reduces leptin production. But the resistance doesn't necessarily resolve in step. People who have lost weight often arrive at a configuration where leptin levels have dropped significantly while hypothalamic sensitivity to the remaining leptin is still impaired. The result is a satiety system running below capacity in two directions at once — less leptin available, and reduced responsiveness to what's there.

This is part of why Sumithran's 2011 follow-up study found that hormonal adaptations to weight loss — including the leptin drop — persisted for at least a year after a calorie-restricted programme. The biology that drives regain is not a transient withdrawal effect. It is a sustained reconfiguration of the satiety system.

The reward circuitry adds another layer

Leptin acts not only on the hypothalamus but also on the mesolimbic dopamine system — the reward circuitry that governs the urgency of food cues. Functional studies have shown that leptin normally tones down the brain's reward response to palatable food. In leptin-resistant states, this brake weakens. Highly palatable food becomes more compelling, not less, even as the homeostatic satiety system is failing to register fullness.

Two systems are now misfiring in the same direction. The brain is underregistering enoughness from the body's energy stores while overregistering the reward value of available calories. The behavioural output — eating past satiety, returning to food between meals, finding it hard to leave food on the plate — is the natural consequence.

This is the configuration that many people with sustained obesity inhabit. It is not a character pattern. It is a measurable shift in hormonal sensing.

Why GLP-1 medications work where leptin didn't

The failure of leptin therapeutics shaped, in part, where the obesity medicine field turned next. GLP-1 receptor agonists — semaglutide, tirzepatide, and the broader class — succeed in part because they bypass the leptin pathway entirely. GLP-1 receptors in the hypothalamus and brainstem operate through different intracellular signalling. They are not resistance-impaired in obesity in the way the leptin system is. The same downstream effect — reduced hunger, increased satiety — is achieved through a route that is still patent.

Hayes and colleagues at the University of Pennsylvania have mapped the central GLP-1 circuitry in detail. The drugs act on POMC neurons in the arcuate nucleus, on the nucleus tractus solitarius in the brainstem, and on reward-circuit areas including the ventral tegmental area and nucleus accumbens. The signalling is independent of leptin and remains functional in leptin-resistant biology. That independence is, in mechanistic terms, the reason these medications produce 15–22% weight loss in clinical trials where leptin produced almost none.

This is also why the framing of obesity as a single-hormone disorder has been superseded by a more integrated model. Multiple satiety and hunger systems shift together in sustained obesity — leptin sensitivity drops, ghrelin signalling persists, reward circuitry intensifies. GLP-1 agonists intervene at a level the leptin system has stopped responding at, which is part of why they work in populations where decades of leptin-focused research never produced a viable therapy.

What this means for an individual

Leptin resistance is not currently measured in standard clinical practice. Fasting leptin levels can be drawn, but interpretation is complicated and the assay rarely changes management. The clinical inference is usually indirect: someone with longstanding obesity, normal thyroid function, and a pattern of difficulty achieving satiety on standard caloric restriction is, in most cases, exhibiting the biology that leptin resistance describes.

The practical implication is not to attempt to "fix" leptin resistance through diet alone. The interventions that have shown some effect on hypothalamic inflammation — reducing ultra-processed food intake, adequate sleep, reduced visceral adiposity — operate slowly and at the margin. They are worth doing. They are rarely sufficient on their own in people whose biology has been in the resistant configuration for years.

For those who meet clinical criteria, the medications that target the satiety system through a different pathway represent the most effective therapeutic option currently available. The framing that obesity is a problem of will, rather than a problem of broken signalling, has cost many people years of self-blame for a condition that doesn't respond to the interventions the framing implies.

Key takeaways

• Leptin was discovered in 1994 by Jeffrey Friedman; the expectation that giving leptin to people with obesity would produce weight loss was tested and largely failed in the 1999 Heymsfield trial.
• People with obesity typically have elevated, not deficient, leptin levels — often three to four times the amount of lean controls.
• The hypothalamus has reduced sensitivity to the signal: impaired blood-brain barrier transport, hypothalamic inflammation, and upregulated SOCS3 all contribute.
• Martin Myers' work at the University of Michigan has mapped the molecular failures; chronic high-fat diets in animals reproduce all three mechanisms.
• Weight loss drops leptin further while sensitivity remains impaired — Sumithran 2011 documented the persistence of these adaptations for at least a year post-diet.
• Leptin also normally tones down the brain's reward response to food; in leptin resistance this brake weakens, intensifying cravings.
• GLP-1 receptor agonists succeed where leptin therapy failed because they signal through pathways that remain functional in leptin-resistant biology.